162 related articles for article (PubMed ID: 14508027)
1. Effects of a behavioral intervention, Tai Chi Chih, on varicella-zoster virus specific immunity and health functioning in older adults.
Irwin MR; Pike JL; Cole JC; Oxman MN
Psychosom Med; 2003; 65(5):824-30. PubMed ID: 14508027
[TBL] [Abstract][Full Text] [Related]
2. Augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of Tai Chi.
Irwin MR; Olmstead R; Oxman MN
J Am Geriatr Soc; 2007 Apr; 55(4):511-7. PubMed ID: 17397428
[TBL] [Abstract][Full Text] [Related]
3. Shingles Immunity and Health Functioning in the Elderly: Tai Chi Chih as a Behavioral Treatment.
Irwin M; Pike J; Oxman M
Evid Based Complement Alternat Med; 2004 Dec; 1(3):223-232. PubMed ID: 15841255
[TBL] [Abstract][Full Text] [Related]
4. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
[TBL] [Abstract][Full Text] [Related]
5. Major depressive disorder and immunity to varicella-zoster virus in the elderly.
Irwin MR; Levin MJ; Carrillo C; Olmstead R; Lucko A; Lang N; Caulfield MJ; Weinberg A; Chan IS; Clair J; Smith JG; Marchese RD; Williams HM; Beck DJ; McCook PT; Johnson G; Oxman MN
Brain Behav Immun; 2011 May; 25(4):759-66. PubMed ID: 21329753
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
[TBL] [Abstract][Full Text] [Related]
7. Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster.
Otani N; Yamanishi K; Sakaguchi Y; Imai Y; Shima M; Okuno T
J Immunol Methods; 2012 Mar; 377(1-2):53-5. PubMed ID: 22261191
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
9. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
Berger R; Luescher D; Just M
Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
[TBL] [Abstract][Full Text] [Related]
10. [Possibility of prevention of herpes zoster by use of varicella vaccine].
Kawano S; Terada K; Yagi Y; Kataoka N
Kansenshogaku Zasshi; 1998 Jul; 72(7):714-9. PubMed ID: 9745221
[TBL] [Abstract][Full Text] [Related]
11. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
Asada H; Nagayama K; Okazaki A; Mori Y; Okuno Y; Takao Y; Miyazaki Y; Onishi F; Okeda M; Yano S; Kumihashi H; Gomi Y; Maeda K; Ishikawa T; Iso H; Yamanishi K;
J Dermatol Sci; 2013 Mar; 69(3):243-9. PubMed ID: 23183011
[TBL] [Abstract][Full Text] [Related]
12. Immune senescence and vaccines to prevent herpes zoster in older persons.
Levin MJ
Curr Opin Immunol; 2012 Aug; 24(4):494-500. PubMed ID: 22857823
[TBL] [Abstract][Full Text] [Related]
13. VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.
Imoto K; Okazaki A; Onishi F; Miyazaki Y; Okeda M; Yano S; Takao Y; Gomi Y; Ishikawa T; Okuno Y; Mori Y; Iso H; Yamanishi K; Asada H;
J Dermatol Sci; 2015 Sep; 79(3):235-40. PubMed ID: 26070505
[TBL] [Abstract][Full Text] [Related]
14. Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.
Shirane R; Tang H; Hayashi K; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
J Med Virol; 2017 Feb; 89(2):313-317. PubMed ID: 27420414
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
[TBL] [Abstract][Full Text] [Related]
16. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.
Schub D; Janssen E; Leyking S; Sester U; Assmann G; Hennes P; Smola S; Vogt T; Rohrer T; Sester M; Schmidt T
J Infect Dis; 2015 Feb; 211(4):600-12. PubMed ID: 25180236
[TBL] [Abstract][Full Text] [Related]
17. Immunization to reduce the frequency and severity of herpes zoster and its complications.
Oxman MN
Neurology; 1995 Dec; 45(12 Suppl 8):S41-6. PubMed ID: 8545018
[TBL] [Abstract][Full Text] [Related]
18. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Kim JW; Min CK; Mun YC; Park Y; Kim BS; Nam SH; Koh Y; Kwon JH; Choe PG; Park WB; Kim I
J Clin Virol; 2015 Dec; 73():64-69. PubMed ID: 26546878
[TBL] [Abstract][Full Text] [Related]
19. VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study.
Asada H
Vaccine; 2019 Oct; 37(44):6776-6781. PubMed ID: 31543415
[TBL] [Abstract][Full Text] [Related]
20. Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects.
Tyring SK; Stek JE; Smith JG; Xu J; Pagnoni M; Chan IS; Silber JL; Parrino J; Levin MJ
Clin Vaccine Immunol; 2012 Sep; 19(9):1411-5. PubMed ID: 22787198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
